A selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies
Life Science Alliance · 2026
DOI: 10.26508/lsa.202503535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2026. Verfasst von Zsolt Szilagyi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Mitochondria, ATP-Dependent Proteases, Mitochondrial Proteins, Proteostasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Knut och Alice Wallenbergs Stiftelse.
Abstract (Originalsprache)
Lon protease 1 (LONP1) is a conserved hexameric protease implicated in mitochondrial disorders and cancer progression. In this study, we present PZL-26, a potent and selective small-molecule inhibitor that targets LONP1 without affecting the proteasome, leading to selective accumulation of mitochondrial proteins. Using PZL-26 in a whole-genome CRISPR-Cas9 screen, we identified genes essential for cell survival under protease inhibition, supporting a role for LONP1 in key mitochondrial processes, including complex I biogenesis, mitochondrial transcription, and translation. Our CRISPR screen results are consistent with proteomics analysis, with both approaches converging on the same mitochondrial pathways and highlighting functional interactions between LONP1 and other mitochondrial proteases, including potential compensatory mechanisms. These findings establish PZL-26 as an effective tool for exploring LONP1 function and pave the way for future therapeutic strategies targeting LONP1 in mitochondrial diseases and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.
- Division of Molecular Metabolism, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
- Pretzel Therapeutics, Mölndal, Sweden.
- Pretzel Therapeutics, Waltham, MA, USA.
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden maria.falkenberg@medkem.gu.se.
- Pretzel Therapeutics, Waltham, MA, USA jgreen@pretzeltx.com.
ORCID-Profile: Carlos Pardo-Hernández, Mãdãlina Sãcultanu, Bertil Macao, Nils-Göran Larsson, Maria Falkenberg, Jeremy Green, Claes M Gustafsson
Förderung
- Vetenskapsrådet
- Cancerfonden
- Knut och Alice Wallenbergs Stiftelse
- EC | European Research Council
- Novo Nordisk Fonden
- Västra Götalandsregionen
- Swedish Brain Foundation
- Swedish Diabetes Foundation
Zitieren
APA
Szilagyi, Z., Michon, P., Pardo-Hernández, C., Sãcultanu, M., Miralles Fusté, J., Griffin, A. M., Charifson, P. S., Phan, C., Shi, Y., Kern, G., Martinez Botella, G., Keating, T. A., Macao, B., Larsson, N. G., Falkenberg, M., Green, J., & Gustafsson, C. M. (2026). A selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies. Life Science Alliance. https://doi.org/10.26508/lsa.202503535
Vancouver
Szilagyi Z, Michon P, Pardo-Hernández C, Sãcultanu M, Miralles Fusté J, Griffin AM, et al. A selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies. Life Science Alliance. 2026. doi:10.26508/lsa.202503535
BibTeX
@article{Szilagyi2026,
author = {Szilagyi, Zsolt and Michon, Pauline and Pardo-Hernández, Carlos and Sãcultanu, Mãdãlina and Miralles Fusté, Javier and Griffin, Andrew M and Charifson, Paul S and Phan, Cindy and Shi, Yonghong and Kern, Gunther and Martinez Botella, Gabriel and Keating, Thomas A and Macao, Bertil and Larsson, Nils-Göran and Falkenberg, Maria and Green, Jeremy and Gustafsson, Claes M},
title = {A selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies},
journal = {Life Science Alliance},
year = {2026},
doi = {10.26508/lsa.202503535}
}
EUVIMED